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Abstract
Introduction: Evidence shows that pre-exposure prophylaxis (PrEP) is highly effective in preventing 
sexually acquired human immunodeficiency virus (HIV) infection. Whilst its implementation is lim-
ited to the US and some countries where demonstration projects have taken place, PrEP has recently 
been introduced in Portugal. Successful implementation of PrEP requires actively engaging and in-
volving of health care providers (HCP) in Portugal, yet little is known about their knowledge, attitudes, 
and acceptability towards this novel intervention. 
Material and methods: An online survey of convenience-sampled Portuguese HCP was conducted in 
January 2016, prior to PrEP implementation, to determine their knowledge, attitudes, practices, and 
acceptability of PrEP. 
Results: A total of 96 respondents nationwide took part in the study, of whom the majority were females 
(60.3%), specialist physicians/junior doctors (39%/53%), working in the  field of  HIV for 1 to 5 years 
(42.3%). Over half (51%) considered having an average or high knowledge of PrEP, and this was more 
common amongst infectious diseases specialists. Major concerns regarding PrEP implementation includ-
ed a rise in sexually transmitted infections and increased antiretroviral resistance. Despite only 31.3% 
being asked about PrEP in the future, the majority (75%) considered that PrEP should be made available 
in Portugal. The main barrier to PrEP implementation was the lack of knowledge and information to HCP. 
Conclusions: Portuguese HCP demonstrated variable degrees of knowledge around PrEP, yet most would 
support its introduction in the country. Concerns were raised about potential consequences of PrEP roll 
out as well as implementation challenges that ought to be addressed before PrEP introduction.
HIV AIDS Rev 2018; 17, 4: 249-258
DOI: https://doi.org/10.5114/hivar.2018.80256
Key words: prevention, HIV/AIDS, Portugal, PrEP. 
Address for correspondence: Dr. Rui Baptista Gonçalves, 
University of Liverpool, School of Medicine, L69 3GE,  
Liverpool, United Kingdom,  
e-mail: rui.baptistagoncalves@online.liverpool.ac.uk
Article history:
Received: 10.12.2017
Received in revised form: 27.03.2018 
Accepted: 02.04.2018 
Available online: 20.11.2018 
RESEARCH PAPER 
Introduction
In recent years, randomized clinical trials have demon-
strated that the  use of  oral tenofovir disoproxil fumarate 
(TDF) regimens as pre-exposure prophylaxis (PrEP) in in-
dividuals at risk of human immunodeficiency virus (HIV) 
infection can significantly reduce their risk of  acquiring 
HIV [1-3]. Although results of those trials differ according 
to targeted populations, PrEP has shown to reduce the risk 
of HIV acquisition in men who have sex with men (MSM), 
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A review from 2012 found only two studies focusing 
on HCP’s awareness and practice of PrEP in the USA [12]. 
The  main concern of  professionals was related to the  lack 
of official guidance, which has subsequently been published 
by both the  Centers for Disease Control and Prevention 
(CDC) and the  WHO. Surprisingly, studies conducted af-
ter those guidelines were published continue to highlight 
a need for more information and guidance for HCP, not only 
in the USA [11, 13, 14] but also in countries were PrEP is being 
considered as a part of HIV prevention programming [15, 16]. 
Additionally, a  qualitative study from 2012 offered further 
insight into the implementation challenges that HCP faced 
at the time PrEP was introduced in the USA, including lack 
of clarity on eligibility criteria and need for additional strat-
egies to be used along with PrEP [17]. 
Whilst the  range of  concerns may have changed over 
time in the USA [18], studies in Canada [15], the UK [16], 
and Italy  [19] demonstrated a  relatively similar degree 
of  knowledge, acceptability, and attitudes towards PrEP. 
Although HCP have variable knowledge of  PrEP in those 
studies, the same key issues are raised in terms of what may 
impact their willingness to prescribe as well as its acceptabil-
ity as an effective prevention tool. Concerns over adherence, 
cost, increase in risk compensation (i.e., the  introduction 
of  PrEP may reduce the  perceived risk of  an  individual’s 
sexual behavior and may cause an  increase in risky sexual 
behaviors) and PrEP’s effectiveness have all been consistent-
ly documented amongst HCP [20]. Nonetheless, acceptabil-
ity levels have been consistently significant and reported in 
the 40-80% range [15, 16, 19, 21, 22]. 
As studies looking at these issues start to emerge in coun-
tries considering PrEP implementation, evidence on HCP’s 
perception of PrEP where it is yet to be implemented, such 
as Portugal, can support public health officials in optimizing 
planning and service delivery of PrEP. Thus, the aim of this 
study is to evaluate HCP’s knowledge, attitudes, practices, 
and acceptability regarding the use of oral PrEP in Portugal. 
Material and methods 
Study design 
This was an observational cross-sectional study of Portu-
guese HCP working with people at risk of HIV. It focused on 
generating evidence on participants’ knowledge, attitudes, 
and practices as well as acceptability towards PrEP. 
Sampling and recruitment 
The study used convenience sampling to recruit partic-
ipants. Eligibility criteria included: being a consenting HCP 
working with people living with or at risk of HIV infection 
in Portugal. Exclusion criteria comprised those who were not 
HCP nor working in supporting people at risk of HIV. 
Between December 2015 and January 2016, eligible par-
ticipants were invited to complete an online survey via email 
through a  range of  professional groups and community- 
heterosexual persons, and people who inject drugs (PWID). 
While there have been concerns about the lack of adherence 
in women participating in two trials, the  evidence from 
studies has consistently shown that adherence is a key pre-
dictor to efficacy of PrEP. Therefore, it is important to high-
light that PrEP requires strict adherence to the regimen be-
ing administered, as this is directly proportional to the level 
of protection. 
In 2015, the World Health Organization (WHO) made 
a strong recommendation that oral PrEP should be offered 
to any person at significant risk for HIV as part of combina-
tion prevention. This recommendation is a  critical step in 
the global response, and underscores that an effective HIV 
prevention programme should feature a  ‘comprehensive 
package’ of interventions, with an aim at reducing the inci-
dence of  HIV infection amongst not just key populations 
but for any individual who is at a  higher risk of  HIV  [4]. 
Prior to the WHO recommendation and in light of the evi-
dence that consistently showed the effectiveness of PrEP [2], 
the  US Food and Drug Administration (FDA) approved 
the  use of  daily tenofovir disoproxil fumarate and emtric-
itabine (TDF-FTC) as a  form of prevention of  sexual HIV 
acquisition [5]. In addition, the European Medicines Agen-
cy (EMA) has recommended granting a  marketing autho-
rization in the  European Union (EU) for TDF-FTC PrEP, 
in combination with safer sex practices to reduce the  risk 
of  sexually-acquired HIV-1 infection in adults at high-
risk [6]. Notably, there are 32 countries with current demon-
stration projects of daily oral PrEP or clinical trials, of which 
five are in the EU region [7]. 
The Portuguese Directorate-General for Health estimated 
that 45,501  [44,470-46,508] people were living with HIV in 
Portugal in 2016 [8]. Sexual transmission remains the main 
route of  HIV transmission, especially among heterosexual 
individuals (57.0% of all new cases in 2016), while MSM ac-
counts for 35.0% of all new HIV cases in 2016 [8]. 
A recent study conducted in Portugal reported that 
59.3% of their participants were eligible for PrEP, following 
the  New York State Department of  Health AIDS Institute 
criteria  [9]. Other study on acceptability of  PrEP among 
110 MSM reported that 41.0% were aware of PrEP. Of these, 
only 20.0% had been informed about PrEP through a health 
care professional (HCP), which can be attributed to both 
reluctance from HCP in discussing PrEP (as it was not yet 
available in Portugal) and lack of information to provide to 
their patients. Furthermore, in that group, 57.0% reported 
that they would take PrEP if available. It is also important to 
highlight that 41.0% of all participants had been engaged in 
unprotected sex in past 6 months [10]. 
Successfully implementing PrEP requires a  continuous 
engagement with HCP in identifying and supporting those 
that can benefit from offering PrEP. Furthermore, well-trained 
professionals are a pivotal agent in ensuring correct prescription 
and monitoring of PrEP users. However, little is known about 
the  readiness, willingness, knowledge, and attitudes towards 
PrEP in HCP. Most studies on this topic have been conducted 
in the USA, where PrEP has been available since 2012 [11]. 
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based organizations. Social media was also employed to dis-
tribute the online survey in selected groups of medical profes-
sionals. All eleven Portuguese hospitals with a department for 
infectious diseases (ID) were also approached by email and/
or by telephone as well as a network of general practitioners 
(GP). Dissemination of information occurred also verbally. 
The broad convenience-sampling strategy did not allow 
estimating the response rate. However, from the current 163 
infectious diseases physicians registered with the Portuguese 
Medical Association in December 2015  [23], 9.8% partici-
pated in this study. 
Data collection and ethical 
considerations 
An online survey was devised for this project, using 
the SurveyMonkey® platform. The questionnaire was adapt-
ed from the study by Desai et al. [16] and based on the liter-
ature review. The questionnaire covered knowledge of PrEP, 
attitudes regarding PrEP, current practice and acceptability 
of PrEP, and demographics. It included a brief explanation 
of  the  study, participants’ informed consent to participate, 
and 23 close-ended questions (multiple choice and Likert 
scale questions). Before was circulated, the survey was pilot-
ed in order to ascertain the feasibility of the questionnaire as 
well as to identify any logistical and/or issues with its struc-
ture and content [24]. 
The study and the instrument were approved by the Di-
rector of the Biomedical Sciences and Medicine Department 
– University of Algarve, prior to data collection. 
Data analysis 
Data from questionnaires were cleaned, exported into 
an Excel spreadsheet, and analyzed for internal consistency. 
IBM® Statistical Package for the Social Sciences (SPSS) ver-
sion 21.0 for Windows (IBM Corp., Armonk, NY, USA) was 
used in all data analysis. 
Descriptive statistics were conducted for sociodemo-
graphic characteristics of  study participants. Furthermore, 
the  Categorical Principal Component Analysis (CATPCA) 
was used to analyze categorical variables. The  choice 
of  a  multivariable technique is linked to the  intention 
of the study to verify to what extent the instrument can be 
applied to the Portuguese population. This methodological 
rationale involves reducing the  dimension of  the  problem 
using CATPCA. Its purpose lies in the  maximum consis-
tency that can be found whilst connecting the  items of all 
considered variables. 
Univariate analysis used a  c2 test of  proportions or 
a two-tailed Fisher’s exact test where figures were less than 
five in any group. Missing data were excluded from statisti-
cal analyses. Likert scales were used to ask questions about 
attitudes to clinical management, patient safety, prioritiza-
tion, and provision of  PrEP. Attitudes were ranked from 
the most negative to the most positive towards PrEP for 
all respondents, and according to respondents’ support or 
non-support of PrEP introduction in Portugal. Uni- and 
multivariable logistic regression analysis was used to iden-
tify which attitudes were barriers to PrEP availability. Sta-
tistical significance was set for p < 0.05. 
Results 
Respondents demographics 
A total of  136 questionnaires were completed, with 
40 being excluded from the  analysis as they did not meet 
the eligibility criteria. After data validation, an additional 18 
questionnaires were excluded due to missing data. Finally, 
78 responses were included in the analysis. 
The majority of  respondents were women, over the  age 
of 30 years, worked in the field of HIV for 1 to 5 years, and 
worked in the North or the Lisbon and the Tagus Valley Re-
gions (Table 1). Sixty-one (78.2%) respondents were doctors, 
being 38.4% senior doctors, and 39.7% junior doctors. Also, 
5 (6.4%) respondents were psychologists, 5 (6.4%) were social 
workers, and 3 (3.8%) were nurses (Table 1). A range of oth-
er professional categories was also recorded as ‘other’ (5.1%) 
including 2 medical students and 2 from other backgrounds. 
Knowledge of pre-exposure 
prophylaxis 
The majority (55.1%) of respondents considered having 
a  high (21.8%) or average (33.3%) knowledge of  PrEP 
(Table 2). Nine (11.5%) participants had never heard 
of PrEP and 26 (33.3%) reported having a low level of knowl-
edge of PrEP (Table 2). Analyzing self-reported knowledge 
of PrEP by profession, doctors (especially senior and junior 
doctors from infectious diseases) accounted for the majori-
ty of those with high level of knowledge of PrEP (Table 2). 
However, both senior and junior GPs showed low or inexis-
tent knowledge of PrEP. All senior GPs felt they did not have 
sufficient knowledge of PrEP to have an informed discussion 
with their patients, while 87.5% of ID senior doctors felt they 
did. No significant differences were found regarding varia-
tions within the sample for all other demographic categories. 
Notably, professionals working in ID had greater awareness 
of the recent WHO guidance on PrEP: only 3 (18.8%) senior 
and 2 (20.0%) junior ID doctors were not aware of the doc-
ument, whereas all GP senior and junior doctors had never 
read or been informed about it. 
A list of PrEP randomised controlled trials (RCTs) was 
presented to ascertain whether respondents were familiar 
with them. More respondents were familiar with the Part-
ners PrEP study (28.1%), followed by the  iPrEX study 
(27.1%), and the  PROUD study (25.0%). However, 59.4% 
of  all respondents had never heard of  any study. This lack 
of awareness of any of the seminal clinical trials was higher 
amongst both senior (90.0%) and junior (80.0%) GPs. 
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The majority of  those supporting PrEP introduction 
in Portugal felt that it should be targeted to seronegative 
partners in a serodiscordant (SD) relationship (60.0%), sex 
workers (56.7%), and all individuals engaging in high-risk 
behaviors (55.0%) (Table 3). Lower percentages were found 
for categories involving one group only, such as PWID 
(26.7%) or MSM (21.3%) (Table 3). 
When questioned on specific aspects of  clinical us-
age of PrEP and crossed with overall support of its intro-
duction in Portugal, results showed that those who did 
not support the  introduction of  PrEP in Portugal were 
more inclined towards disagreeing with a  broadened 
access of  PrEP (66.7% vs. 10.0%; p  <  0.01), considering 
PrEP as an inefficient preventative tool (61.1% vs. 11.7%; 
p  <  0.01) and not feeling comfortable with prescribing 
PrEP without specific guidelines (83.3% vs. 60.0; p = 0.07) 
(Table 4). 
When focusing on access, cost effectiveness of PrEP, 
and governmental funding, 56.4% of  respondents dis-
agreed that it should be simply offered to those who 
request it. The  majority (73.1%) agreed that it should 
only be provided to those at increased risk of  contract-
ing HIV. The prescription regimen that achieved greater 
concordance was that of  making PrEP available but be-
ing the cost only partly subsidized by the National Health 
Service (50.0%). 
CATPCA was then employed to allow identifying 
the underlying components of a set of attitude-related items, 
while maximizing the amount of variance accounted for in 
those items (by the  principal components). According to 
the Chronbach’s α, two broader and statistically consistent 
dimensions were observed that were then designated by ‘in-
difference’ and ‘concern’ towards potential PrEP users, trans-
lated by consistent values of α quantified by 0.854 and 0.730, 
respectively. 
The multivariable logistic model shows that the odds 
ratio for HCP supporting PrEP availability in Portugal 
was lowest when disagreeing with the  statement ‘PrEP 
should be widely available based on current evidence’ 
(p < 0.01), which suggests that, not surprisingly, this at-
titude is the  greatest barrier to support PrEP introduc-
tion in Portugal (Table 5). The second barrier identified 
in the multivariable logistic model was the concern that 
patients who take PrEP would be mistakenly labelled as 
HIV-positive (p = 0.01). Other attitudes were important 
predictors in the univariate model but not in the multi-
variable model (Table 5). Disagreeing with ‘PrEP being 
an  effective preventive tool based on current evidence’, 
and that ‘PrEP will have a greater impact than behavioral 
intervention in preventing HIV infection’ were significant 
at 5% level in the univariate but not in the multivariable 
model (Table 5). 
With respect to acceptability, participants were asked 
to rate a number of aspects, which could negatively im-
pact the implementation of PrEP in Portugal (Fig. 1). An-
swers were grouped in three categories: Agree (covering 
Attitudes to pre-exposure 
prophylaxis 
Despite variable knowledge of  PrEP, most respondents 
(76.9%) considered that PrEP should be made available in 
Portugal in light of the current evidence (Table 4). This was 
particularly the  case among nurses (100.0%), GP senior 
doctors (90.0%), followed by junior ID doctors (80.0%), and 
social workers (80.0%) (p = 0.99). ID senior doctors repre-
sented a  lower percentage (68.8%) of supporters of  the  in-
troduction of PrEP in Portugal, only to be overcome by psy-
chologists (60.0%). 
Table 1. Respondents demographics 
Factor n (%)
Gender 78 (100.0)
Male 31 (39.7)
Female 47 (60.3)
Age 78 (100.0)
< 29 25 (32.1)
30-39 38 (48.7)
40-49 8 (10.3)
50-59 5 (6.4)
≥ 60 2 (2.6)
Time working on HIV 78 (100.0)
< 1 year 10 (12.8)
1 to 5 years 33 (42.3)
6 to 15 years 28 (35.9)
> 15 years 7 (8.9)
Region 78 (100.0)
North 25 (32.1)
Centre 17 (21.8)
Greater Lisbon 25 (32.1)
South 9 (11.5)
Islands (Madeira/Azores) 2 (2.6)
Profession 78 (100.0)
Doctor 61 (78.2)
Nurse 3 (3.8)
Psychologist 5 (6.4)
Social worker 5 (6.4)
Other 4 (5.1)
Doctors by medical category 61 (100.0)
Senior ID 16 (26.2)
Senior GP 10 (16.4)
Senior (other) 4 (6.6)
Junior ID 10 (16.4)
Junior GP 5 (8.2)
Junior (other) 16 (26.2)
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those who agreed or strongly agreed), Undecided, and 
Disagree (for those disagreeing or strongly disagreeing). 
The main concerns regarding the implementation of PrEP 
in Portugal were lack of  information of  HCP, followed by 
lack of specific guidelines to regulate PrEP dispense, and cost 
for the  user (assuming no coverage from the  government). 
The aspect that less concerned respondents was lack of inter-
est in PrEP from key populations (Fig. 1). 
Practice of pre-exposure prophylaxis 
A total of 32.1% of  respondents reported to have been 
ever asked for information and advice on PrEP (Table 6). 
This proportion was higher among doctors (72.0%), partic-
ularly ID senior (44.0%), and junior (12.0%) doctors. How-
ever, the  large majority (67.9%) of  respondents had never 
been asked about PrEP. Among those who were ever asked 
about PrEP, the majority (52.0%) were asked 1 to 5 times in 
Table 2. Reported knowledge of pre-exposure prophylaxis (PrEP), by professional group 
Factor
Overall
n (%)
Professional group 
n (%)
Doctor
n = 61
Nurse
n = 3
Psychologist
n = 5
Social worker
n = 5
Other
n = 4
Knowledge of PrEP
High 17 (21.8) 13 (21.3) 2 (66.7) 1 (20.0) 0 (0.0) 1 (25.0)
Average 26 (33.3) 19 (31.1) 0 (0.0) 2 (40.0) 3 (60.0) 2 (50.0)
Low 26 (33.3) 20 (32.8) 1 (33.3) 2 (40.0) 2 (40.0) 1 (25.0)
Inexistent/never heard of it 9 (11.5) 9 (14.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Aware of RCTs
iPrEx 26 (33.3) 22 (36.1) 3 (100.0) 0 (0.0) 0 (0.0) 1 (25.0)
FEM-PREP 12 (15.4) 9 (14.8) 1 (33.3) 0 (0.0) 1 (20.0) 1 (25.0)
CDC-TDF2 11 (14.1) 8 (13.1) 2 (66.7) 0 (0.0) 0 (0.0) 4 (100.0)
Partners PrEP 25 (32.1) 20 (32.8) 2 (66.7) 2 (40.0) 0 (0.0) 1 (25.0)
VOICE 6 (7.7) 4 (6.6) 1 (33.3) 0 (0.0) 0 (0.0) 1 (25.0)
PROUD 24 (30.8) 19 (31.1) 2 (66.7) 2 (40.0) 0 (0.0) 1 (25.0)
Not aware of any RCT 42 (53.8) 32 (52.5) 0 (0.0) 3(60.0) 4 (80.0) 0 (0.0)
RCTs – randomised controlled trials
Table 3. Distribution of target groups to which pre-exposure prophylaxis should be offered if available, by professional group 
Target groups
Overall 
n (%)
Professional group 
n (%)
Doctor Nurse Psychologist Social worker Other
Sexually active MSM 18 (30.0) 13 (72.2) 2 (11.1) 1 (5.6) 0 (0.0) 2 (11.1)
MSM with recurrent STIs 25 (41.7) 20 (80.0) 1 (4.0) 1 (4.0) 1 (4.0) 2 (8.0)
All MSM 13 (21.7) 11 (84.6) 1 (7.7) 0 (0.0) 0 (0.0) 1 (7.7)
All sexually active people with multiple partners 20 (33.3) 17 (85.0) 2 (10.0) 0 (0.0) 0 (0.0) 1 (5.0)
Sex workers 34 (56.7) 28 (82.3) 2 (5.9) 2 (5.9) 0 (0.0) 2 (5.9)
People who inject drugs 16 (26.7) 12 (75.0) 1 (6.3) 1 (6.3) 0 (0.0) 2 (12.4)
All seronegative people in a monogamous SD 
relationship
36 (60.0) 30 (83.2) 1 (2.8) 1 (2.8) 2 (5.6) 2 (5.6)
Only seronegative MSM in a SD relationship 2 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 1(50.0)
Only seronegative people in a SD relationship 
trying to conceive
5 (8.3) 5 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
All risk takers 33 (55.0) 25 (75.7) 2 (6.1) 1 (3.0) 2 (6.1) 3 (9.1)
Other 7 (11.7) 5 (71.4) 2 (28.6) 0 (0.0) 0 (0.0) 0 (0.0)
Note: Respondents were asked to select all that apply  
MSM – men who have sex with men, STIs – sexually transmitted infections, SD – serodiscordant
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the  past year (Table 6), and consisted mostly of  ID senior 
doctors and psychologists. 
Discussion 
Portugal has historically and consistently been the coun-
try with the highest incidence of HIV infection in Western 
Europe [25]. In the current Portuguese National HIV Pro-
gramme, prevention has been identified as one of  the  key 
priorities for action  [26]. PrEP is an  effective tool in HIV 
prevention, and it is likely that its introduction in Portugal 
will take place in the near future. 
This is the first nationwide survey to assess the knowl-
edge, attitudes, practices, and acceptability of PrEP among 
HCP in Portugal. When compared to previous studies 
with HCP [13-15], the  study has sampled a broader range 
of medical specialties and professional categories. It is cur-
rently being suggested that PrEP implementation should 
engage a  wider array of  HCP rather than solely senior ID 
doctors [12, 18, 22, 27]. The study also surveyed HCP from 
all regions of the country, thus eliciting the insight of profes-
sionals in assorted contexts. 
Our study revealed that most respondents were some-
what familiar with PrEP, which was not surprising given that 
most participants in our study were doctors. However, a de-
gree of unawareness was noted among GPs, which corrobo-
rates studies conducted in this group [13, 18]. 
Being familiar with PrEP positively influenced the con-
fidence in discussing PrEP with potential users as well as 
being aware of  the  state of  the art concerning research on 
PrEP, which also supports the current evidence [25]. 
The study found a  strong support for the  introduction 
of PrEP in Portugal, particularly if aimed at those at increased 
risk for HIV infection, and within the cost being partly sup-
ported by the user (partial subsidy by the NHS). This find-
ing is consistent with what has been reported from studies 
conducted in the  USA  [28], the  UK  [16], and Italy  [19], 
but approval rate was lower among the  Canadian counter-
parts  [15]. As shown in the  British study  [16], support for 
introduction of PrEP was higher amongst senior ID doctors. 
The study did not report specific reasons for disapproval but 
highlighted a  number of  important challenges that may be 
potential motives. In our survey, PrEP non-supporters were 
likely to answer that it would have less impact on the epidem-
ic when compared to other behavioral preventative strategies. 
This group was also skeptical about PrEP effectiveness and, if 
introduced in Portugal, they would support restricted access 
to selected potential users. This may reflect existing concerns 
over whether implementing PrEP will obtain similar results 
as those reported in clinical trials, in spite of the strong ev-
idence to support its biological efficacy and early guidance, 
and the endorsement by the CDC and the WHO. The lack 
of European population data, wide range of adherence rates 
to PrEP across the different RCTs, and the lack of long-term 
PrEP efficacy and safety data to demonstrate significant 
‘real-world’ impact may explain such apprehensions. 
Concerns over adherence and side effects were less 
pronounced in our study, when compared with other stud-
ies [16, 22, 28, 29]. Nevertheless, both PrEP supporters and 
non-supporters agreed that PrEP may lead to an  increase 
in sexually transmitted infections (STIs) and antiretrovi-
ral therapy (ART) resistance, which has also been reported 
in the  literature  [19, 28]. However, data from randomized 
controlled trials of PrEP suggest that risk of drug resistance 
is low, occurring in approximately 1 in 1,000 PrEP users in 
clinical trials  [3]. PrEP-selected resistance was observed 
in the FEM-PrEP study, but this was not frequent [30]. Finally, 
although some modelling studies suggest a  small increase 
in HIV drug resistance associated with PrEP roll-out, this is 
not likely to be a major contributor to resistance, if PrEP im-
plementation includes routine monitoring of HIV infection 
status to limit the possible spread of drug resistance [31].
The  concerns expressed by respondents in this study 
suggest a  limited understanding of  PrEP RCTs (53.8% 
of respondents in our survey were not aware of any RCT). 
Therefore, PrEP implementation in Portugal should ad-
Figure 1. Distribution of Health care providers’ agreement with key negative aspects influencing pre-exposure prophylaxis 
(PrEP) availability
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dress the dissemination of PrEP in literature that describes 
the seminal PrEP trials and presents evidence from the trials 
in a way that accurately informs HCP. 
Respondents considered that PrEP implementation 
would be most affected by a lack of information and guid-
ing specifically targeting HCP, coupled with costs associ-
ated with PrEP. A spectrum of studies has highlighted this 
need for guidelines and training focused on HCP as PrEP 
is introduced in settings  [14-17, 21]. Notably, in contrast 
to the Italian study [19], most Portuguese HCP do not feel 
comfortable in prescribing PrEP without specific guidance. 
Regarding cost, our study highlights a level of apprehension 
towards introducing a  potentially expensive preventative 
intervention that may detract funding from other areas. 
The international debate on the role of PrEP in the HIV re-
sponse has also reflected upon this issue [11, 16]. 
Our current study is consistent with the  literature in 
terms of  what respondents thought would be groups that 
were most likely to receive PrEP [19, 28]. Most respondents 
would offer PrEP to SD partners and people at higher risk 
for HIV, which may highlight the need to inform providers 
how to prioritize and identify people at risk that can benefit 
Table 4. Variation of agreement and disagreement levels between pre-exposure prophylaxis (PrEP) supporters and non-sup-
porters regarding clinical management, safety, access, and governmental funding for PrEP 
Statement
Agrees or strongly agrees, n (%) Disagrees or strongly disagrees, n (%)
PrEP supporters
n = 60
Non-supporters 
of PrEP
n = 18
p-value
PrEP 
supporters
n = 60
Non-supporters 
of PrEP
n = 18
p-value
PrEP should be widely available 
based on current evidence 
43 (71.7) 2 (11.1) < 0.01* 6 (10.0) 12 (66.7) < 0.01*
I think PrEP will not be 
an effective preventive tool 
based on current evidence
7 (11.7) 11 (61.1) < 0.01* 33 (55.0) 1 (5.6) < 0.01*
I feel comfortable in prescribing 
PrEP without specific guidelines
10 (16.7) 1 (5.6) 0.23 36 (60.0) 15 (83.3) 0.07
Truvada® is a safe drug that can 
be used as PrEP
33 (55.0) 2 (11.1) < 0.01* 1 (1.7) 6 (33.3) < 0.01*
The use of PrEP will have little 
impact on ART resistance
15 (25.0) 1 (5.6) 0.07 19 (31.7) 10 (55.6) 0.07
PrEP will have greater impact 
than behavioral intervention on 
preventing HIV infection
24 (40.0) 2 (11.1) 0.02* 23 (38.3) 13 (72.2) 0.01*
The use of PrEP will lead to 
an increase in STIs
28 (46.7) 12 (66.7) 0.14 19 (31.7) 1 (5.6) 0.03*
I worry that those who use PrEP 
are mistakenly labelled as HIV-
positive
29 (48.3) 1 (5.6) < 0.01* 18 (30.0) 11 (61.1) 0.02*
I worry that those who use PrEP 
will be stigmatized
25 (41.7) 3 (16.7) 0.05 16 (26.7) 11 (61.1) < 0.01*
PrEP should be made available 
to all those who request it
15 (25.0) 0 (0.0) 0.02* 29 (48.3) 15 (83.3) < 0.01*
PrEP should be made available 
only to those at high risk of HIV 
infection
50 (83.3) 7 (38.9) < 0.01* 4 (6.7) 4 (22.2) 0.06
PREP should be made available, 
but the total cost must be 
covered by the user only
11 (18.3) 4 (22.2) 0.71 30 (50.0) 7 (38.9) 0.41
PREP should be made available 
and the cost should be partially 
covered by the user
34 (56.7) 5 (27.8) 0.03* 13 (21.7) 9 (50.0) 0.02*
PREP should be made available 
at no cost for the user
18 (30.0) 1 (5.6) 0.03* 25 (41.7) 14 (77.8) < 0.01*
*Statistically significant at 5% level 
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Table 6. Practice of pre-exposure prophylaxis (PrEP), by professional group availability
Overall, 
n (%)
Professional group, n (%)
Doctor
n = 61
Nurse
n = 3
Psychologist
n = 5
Social worker
n = 5
Other
n = 4
Ever asked about PrEP by patients 78 (100.0)
Yes 25 (32.1) 18 (29.5) 2 (66.7) 4 (80.0) 0 (0.0) 1 (25.0)
No 53 (67.9) 43 (70.5) 1 (33.3) 1 (20.0) 5 (100.0) 3 (75.0)
Number of times asked about PrEP by patients 
in the past 12 months 
25 (100.0)
0 5 (20.0) 5 (27.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1–5 13 (52.0) 10 (55.6) 0 (0.0) 3 (75.0) 0 (0.0) 0 (0.0)
> 10 7 (28.0) 3 (16.7) 2 (100.0) 1 (25.0) 0 (0.0) 1 (100.0)
from PrEP. It also reflects the effect of current practice, given 
the fact that a third of study sample had already been asked 
for information on PrEP (mostly by SD partners and MSM). 
This further underscore the need to develop specific guid-
ance for Portuguese HCP. 
The only previous survey looking at PrEP acceptabili-
ty in Portugal aimed at MSM revealed that more than half 
of  those surveyed were willing to use PrEP, highlighting 
a level of interest from the users’ perspective [12]. Further-
more, it showed that HCP were not the main source of in-
formation on PrEP for that sample, which further enhances 
the  need to supply HCP with knowledge and support on 
the range of issues that encompass PrEP and its implemen-
tation. Given the latest WHO recommendation on compre-
hensive packages for HIV prevention, PrEP is at the  core 
of potentially offering a solution to curtail the epidemic [32]. 
Our study presents a pragmatic starting point to assess ac-
ceptability towards PrEP on a group of key stakeholders in 
its eventual implementation. 
There were some notable limitations in our study. Firstly, 
there is some weakness associated with the number of respon-
dents and the use of convenience sampling, which hindered 
the correct estimation of the response rate. The study would 
have benefited from a more in-depth analysis of  the demo-
graphic variables, with particular emphasis on geographic ref-
erencing analyzed in conjunction with the remaining statisti-
cal outputs. Details on marital status, religion, HIV status, and 
sexual orientation of  the  sample would also have helped to 
understand whether these influenced the results. Unlike other 
studies [19], time constraints did not permit a longer period 
to survey completion and possible qualitative interviews to 
inform our survey. 
Participation was voluntary, and therefore not all eligible 
candidates may have been willing to complete the survey, al-
beit having accessed and/or being aware of it; there may be 
systematic bias between the types of participants who chose 
to respond and those who did not. An online survey might 
carry some disadvantages, namely issues of Internet access 
or potential lack of  cooperation for excessive demand to 
participate in similar studies. These were mitigated, to some 
extent, by following-up on all of those who were approached 
to assist with recruitment. 
Table 5. Odds ratios of supporting pre-exposure prophylaxis (PrEP) availability when the respondent strongly disagreed with/
disagreed with/undecided about the attitude statement 
Attitude statement
Univariable OR 
(95% CI)
p-value
Multivariable OR  
(95% CI)
p-value
PrEP should be widely available based on current evidence 0.05 (0.01-0.24) < 0.01* 0.03 (0.03-0.25) < 0.01*
PrEP effective preventive tool based on current evidence 0.09 (0.02-0.29) < 0.01* 0.24 (0.04-1.53) 0.13
Comfortable prescribing PrEP without specific guidelines 0.29 (0.04-2.47) 0.26 0.66 (0.01-51.22) 0.85
Truvada® safe drug for PrEP 0.41 (0.14-1.23) 0.11 0.44 (0.39-4.91) 0.50
Little impact of PrEP on ART resistance 0.18 (0.20-1.44) 0.11 1.93 (0.08-46.83) 0.69
PrEP will have greater impact than behavioral interventions on 
preventing HIV infection
0.18 (004-0.84) 0.03* 0.38 (0.01-4.77) 0.46
PrEP will not lead to an increase in STIs 2.29 (0.76-6.89) 0.14 3.95 (0.48-32.58) 0.20
Lack of labelling for patients on PrEP 0.06 (0.01-0.50) < 0.01* 0.04 (0.01-0.52) 0.01*
Lack of stigma for patients on PrEP 0.28 (0.07-1.07) 0.06 0.46 (0.05-4.01) 0.48
*Statistically significant at 5% level 
CI – confidence interval, OR – odds ratio, STIs – sexually transmitted infections, ART – antiretroviral therapy
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Other limitations relate to the  type of  instrument used. 
Likert scales have been known to encompass a  number 
of drawbacks [33], namely respondents’ avoidance to use ex-
treme response categories (central tendency bias), agreement 
with statements as presented (acquiescence bias), or trying to 
portray themselves in a more favorable light (social desirabil-
ity bias). In this study, acquiescence bias may be dissipated by 
the use of  a balanced scale. Similarly, previous studies have 
shown that online surveys have the potential to limit social 
desirability bias [19, 34]. Multi-scale items validity check us-
ing test-retest was not conducted, but inter-reliability analysis 
of Chronbach’s α confirmed internal consistency. Given that 
the study was conducted prior to the implementation of PrEP 
in the country, it would be beneficial to appraise whether these 
attitudes, knowledge and acceptability have changed with the 
introduction of PrEP across the country.
Conclusions 
The implementation of PrEP in Portugal requires active 
engagement with HCP and other stakeholders in health ser-
vice provision. As HCP are instrumental in implementing 
a  new intervention; it is critical to have a  nuanced under-
standing of their knowledge and acceptability of PrEP. Our 
study highlighted the wider acceptability of Portuguese HCP 
towards PrEP in a moment its introduction in the country 
was being discussed but not yet in course. 
In addition, our survey demonstrated that Portuguese 
HCP were willing to support PrEP implementation efforts, 
but a  range of  issues related to specific guideline develop-
ment, PrEP education programs to HCP, and public financ-
ing to potential users must be addressed. Our study also 
showed that levels of knowledge varied between profession-
al groups, which further accentuates the need for guidance 
and training on PrEP to HCP. Moreover, specific issues such 
as lack of information for HCP and cost were identified as 
potential implementation challenges, which must be taken 
into account if and when PrEP is implemented in Portugal. 
Finally, the results have contributed to our understand-
ing of HCP baseline knowledge, attitudes, practice, and ac-
ceptability towards PrEP, and help to fill a  knowledge gap 
in this issue. It also postulated important findings with re-
gards to how these were organized, eliciting diverse degrees 
of awareness with regard to distinct levels of support. Fur-
ther research should help to understand concerns related to 
PrEP raised by HCP in this study. 
Bearing in mind the epidemiological trends of HIV in-
fection in Portugal, engaging with novel preventative and 
cost-effective approaches such as PrEP may carry sufficient 
public health impact to curb the epidemic. 
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